IMC-C103C

P1/2, N=75, Terminated, Immunocore Ltd | N=144 --> 75 | Trial completion date: Feb 2024 --> Sep 2023 | Active, not recruiting --> Terminated; The Sponsor terminated the study and there is no further enrollment. Endpoints will not be assessed for this trial.

P1/2, N=144, Active, not recruiting, Immunocore Ltd | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Feb 2024 | Trial primary completion date: Jul 2025 --> Sep 2023

Pre-selection for MAGE-A4 expression was not required as a majority of OC express MAGE-A4 (H score ≥ 1) and tebentafusp demonstrated OS benefit and ctDNA reductions regardless of H score, although RECIST responses were enriched at higher H scores (Leach 2021). IMC-C103C is clinically active but the low MAGE expression may have resulted in few RECIST responses. Dose optimization and signal detection continue in MAGE-A4 pos pts with additional tumor types.

Background TCR bispecific proteins (bsp) redirect polyclonal T cells to target intra/extracellular proteins in cancer, as validated by tebentafusp (CD3×gp100 TCR) with a survival benefit in metastatic uveal melanoma (HR 0.51). Legal entity responsible for the study Immunocore Ltd. Funding Immunocore Ltd.

P1/2, N=144, Recruiting, Immunocore Ltd | Trial completion date: Apr 2023 --> Jul 2025 | Trial primary completion date: Oct 2021 --> Jul 2025

Tebentafusp is being further evaluated in combination with durvalumab and tremelimumab. IMC-C103C monotherapy dose escalation is in progress. Research Funding: Immunocore Ltd, Pharmaceutical/Biotech Company